Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Receivables Change in Receivables Change in Taxes Change in Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased

Daily Values

Growth Metrics

Others

Anaptysbio (ANAB) Non-cash Items (2024 - 2025)

Anaptysbio filings provide 2 years of Non-cash Items readings, the most recent being $3.8 million for Q4 2025.

For the quarter ending Q4 2025, Non-cash Items rose 611.07% year-over-year to $3.8 million, compared with a TTM value of $3.8 million through Dec 2025, up 611.07%, and an annual FY2025 reading of $3.8 million, up 611.07% over the prior year.
Non-cash Items hit $3.8 million in Q4 2025 for Anaptysbio, up from $534000.0 in the prior quarter.
The five-year high for Non-cash Items was $3.8 million in Q4 2025, with the low at $534000.0 in Q4 2024.